Value Adjusted for Debt and Cash: Scholar Rock (SRRK)

Brandmark of Scholar Rock Inc. (SRRK)

Scholar Rock (SRRK) is developing innovative treatments for muscle atrophy, relying on patent protection to establish significant pricing power. Research and development in neuropathologies and muscular dystrophy are backed by robust capital, ensuring stability until products reach the market. The company's environmental profile is limited to basic waste disposal. The current asset value, as reflected in the pakistan asset value chart, is 5092.21.

SRRK scholarrock.com: Total Company Value in the range 11/23/2025 - 10/30/2026

Scholar Rock (SRRK) - metric breakdowns and financial figures

- stock quotes and analyst forecast:
Price Performance Chart Scholar Rock, Inc.|SRRK - Price Target Chart
- company stock exchange capitalization indicators:
Market Value Scholar Rock|SRRK - Total Company Value
- book capitalization information:
Book Value per Share Scholar Rock|SRRK - Company Book Value|Market Capitalization to Net Assets scholarrock.com|SRRK - Company Total Assets
- debt level and financial liquidity data:
All Debt to Shareholders' Equity Ratio Scholar Rock|SRRK - Long-Term Debt to Capital|Short-Term Debt to Capital scholarrock.com|SRRK - Company Debts|Debt to Net Assets Ratio Scholar Rock|SRRK - Company Long-Term Debt|Company Current Liabilities Scholar Rock|Quick Ratio scholarrock.com
- business earnings and investment ratios data:
SRRK - Net Income
Analysis of all company metrics:Scholar Rock, Inc.
Brand item of Scholar Rock

Enterprise Value (EV) combines market capitalization and net debt, reflecting the actual cost of a full business buyout accounting for all liabilities and liquidity. By analyzing fluctuations in enterprise value, an investor can assess how the diversified development portfolio of Scholar Rock (SRRK) in myology and oncology impacts the company's overall investment attractiveness and financial stability.

Competitors of Scholar Rock (SRRK)

Value Adjusted for Debt and Cash JAZZ|CYTK - Total Company Value|Value Adjusted for Debt and Cash PTCT (PTC Bio)|Centessa Pharmaceuticals (CNTA) - Total Company Value|dyne-tx.com (DYN) - Enterprise Value|Total Company Value Edgewise Therapeutics, Inc.|Rapport Therapeutics Inc - Full Business Value|Enterprise Value ALMS|ZVRA (Zevra Corp) - Value Adjusted for Debt and Cash|Enterprise Value CTNM (Contineum Therapeutics, Inc.)|Enterprise Value larimartx.com LRMR|CAPR - Total Company Value|Value Adjusted for Debt and Cash TRDA (Entrada Therapeutics Inc.)|Channel (PTHS) - Total Company Value|Real Price to Acquire Entire Company MediciNova|SER (Serina Therapeutics, Inc.) - Enterprise Value|Enterprise Value bioxceltherapeutics.com|Real Price to Acquire Entire Company PMN (ProMIS Neurosciences)|APUS (apimedsus.com) - Value Adjusted for Debt and Cash|Total Company Value AEON Biopharma, Inc. AEON|NLSP: Business Value|Bionomics Ltd - Enterprise Value|Total Enterprise Value fsdpharma.com|RETA (Reata Pharmaceuticals, Inc.) - Real Price to Acquire Entire Company